Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out…
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually…
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question…
Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two very different futures in oncology. One company is collecting cash…
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate.…
Both McDonald's and Pfizer are blue-chip laggards trading at a discount, both cut reliable dividend checks, and both promise retirees a place to park serious money. But one of them carries hidden…
Jim Cramer stared down a stock yielding over 6% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC's Mad…
Danielle Liverance The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker:…
Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines…
The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. That is exactly where…
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash,…
Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but…
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th…
Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat…
